Case-control studies of the association of colchicine use and myocardial infarction (MI) among gout patients in The Health Improvement Network
| MI cases | Controls | OR, Fully adjusted* | |
|---|---|---|---|
| (N=974) | (N=4762) | (95% CI) | |
| A. Recency of colchicine use among MI cases and matched controls | |||
| Never use, N (%) | 763 (78.3%) | 3838 (80.6%) | 1.0 (Ref) |
| Current use, N (%) | 20 (2.1%) | 91 (1.9%) | 0.96 (0.58–1.60) |
| Recent use, N (%) | 45 (4.6%) | 158 (3.3%) | 1.49 (1.05–2.11) |
| Past use, N (%) | 146 (15.0%) | 675 (14.2%) | 1.12 (0.91–1.38) |
| B. Number of colchicine prescriptions in the previous year among MI cases and matched controls | |||
| Zero prescriptions, N (%) | 877 (90.0%) | 4382 (92.0%) | 1.0 (Ref) |
| 1 prescription, N (%) | 61 (6.3%) | 249 (5.2%) | 1.31 (0.97–1.78) |
| 2 prescriptions, N (%) | 20 (2.1%) | 64 (1.3%) | 1.50 (0.88–2.55) |
| 3–5 prescriptions, N (%) | 13 (1.3%) | 46 (1.0%) | 1.35 (0.72–2.55) |
| ≥6 prescriptions, N (%) | 3 (0.3%) | 21 (0.4%) | 0.62 (0.18–2.10) |
↵* Adjusted for BMI, hypertension, diabetes mellitus, number of GP visits in previous year, smoking, alcohol use, and use of ACE inhibitors, aspirin, beta-blockers, gout drugs (allopurinol, febuxostat, probenicid, sulfinpyrazone and benzbromarone), lipid-lowering agents and NSAIDs. Ref = referent group; OR = Odds Ratio.